Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Chris Waddell Abbott

Abbott executive who led TAVR, Tendyne divisions announces exit

Chris Waddell, a medtech executive focused on various structural heart technologies, is leaving Abbott after several years to "recharge" and pursue a new opportunity.

Robotic aortic valve replacement (RAVR) is a new minimally invasive treatment option for symptomatic severe aortic stenosis (AS) that uses advanced robotic surgical systems. It has already started gaining momentum as an alternative to both surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR).

Robotic cardiac surgery building momentum thanks to RAVR, other breakthroughs

The sky may be the limit for robotic cardiac surgery in 2026 and beyond.

The DurAVR TAVR system from Anteris Technologies

Medtronic invests $90M in medtech company behind one-of-a-kind TAVR tech

Anteris Technologies is known for its biomimetic transcatheter heart valve, the DurAVR THV System. The device is the first of its kind and has gained considerable attention as the TAVR market continues to grow.

business money suit investor

Abbott’s medtech sales climbed in Q4 thanks to strength of heart devices

Abbott pointed to double-digit growth for its Navitor TAVR valve as well as big gains for the TriClip and MitraClip devices. The company also shared positive sales figures for its EP, heart failure and rhythm management portfolios. 

female physician male

Medical societies, medtech companies and clinicians weigh in as CMS considers sweeping TAVR changes

CMS is considering substantial updates to its TAVR policies, including coverage for asymptomatic patients. Some stakeholders are excited, embracing the possibility of expanded indications and fewer restrictions. Others are concerned that the changes would be too much, too soon.

heart data research doctor cardiologist AI

Post-TAVR echocardiography helps predict a patient’s long-term risk of SVD

Postprocedural gradients can tell cardiologists a lot about a patient's long-term risk of structural valve deterioration.

Abbott’s Navitor TAVR valve linked to positive real-world outcomes

The intra-annular, self-expanding Navitor valve gained FDA approval in 2023 for the treatment of high-risk heart patients with severe aortic stenosis. This analysis explores its early impact on patient care. 

cardiologist patient heart compensation starting salary 2022 interventional cardiologist

TAVR’s next big challenge: Providing consistent relief for heart patients with aortic regurgitation

TAVR has already transformed care for patients with severe aortic stenosis. Will it make a similar impact on the treatment of aortic regurgitation?

Displaying 9 - 16 of 1111
Design by Adaptive Theme